ArticleTheranostics2024
Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy.
Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The potential value of curcumin in breast cancer: a systematic review and meta-analysis of preclinical studies.Frontiers in pharmacology · 2026Pooled it
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Article
- Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.Medical oncology (Northwood, London, England) · 2026Review
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Curcumin-mediated modulation of immunogenic cancer cell death pathways.Molecular biology reports · 2026Review
- Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLC.NPJ precision oncology · 2026Article
- Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Research Progress on the Regulatory Effect of Curcumin on Mesenchymal Stem Cells.International journal of molecular sciences · 2026Review
- Research Progress of Multicomponent Co-Loaded Nanomedicine Delivery Systems for Tumor Immunotherapy.International journal of nanomedicine · 2026Review
- PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts.Materials today. Bio · 2025Article
- Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines.International journal of molecular sciences · 2025Review
- Engineered Cancer Cell Membrane-Functionalized Metal-Organic Frameworks for Irinotecan/Curcumin Codelivery in Colorectal Cancer: Enhanced Efficacy and Mitigated Toxicity.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.